Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Abiraterone in metastatic prostate cancer.

Raymond LW, Carr JP, Only C.

N Engl J Med. 2013 Apr 11;368(15):1457-8. doi: 10.1056/NEJMc1301594#SA2. No abstract available.

PMID:
23574135
2.

Abiraterone in metastatic prostate cancer.

Kichenadasse G, Karapetis C.

N Engl J Med. 2013 Apr 11;368(15):1457. doi: 10.1056/NEJMc1301594#SA1. No abstract available.

PMID:
23574134
3.

Abiraterone in metastatic prostate cancer.

Ryan CJ, Molina A, Griffin T.

N Engl J Med. 2013 Apr 11;368(15):1458-9. doi: 10.1056/NEJMc1301594. No abstract available.

4.

Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

Taneja SS.

J Urol. 2013 Sep;190(3):880. doi: 10.1016/j.juro.2013.05.104. No abstract available.

PMID:
23931193
6.

Drug helps slow advanced prostate cancer.

Printz C.

Cancer. 2012 Oct 1;118(19):4641. doi: 10.1002/cncr.27828. No abstract available.

7.

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.

Chi KN, Tolcher A, Lee P, Rosen PJ, Kollmannsberger CK, Papadopoulos KP, Patnaik A, Molina A, Jiao J, Pankras C, Kaiser B, Bernard A, Tran N, Acharya M.

Cancer Chemother Pharmacol. 2013 Jan;71(1):237-44. doi: 10.1007/s00280-012-2001-0.

PMID:
23064959
8.

Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.

Tagawa ST, Beltran H.

Asian J Androl. 2011 Nov;13(6):785-6. doi: 10.1038/aja.2011.113. No abstract available.

9.

Abiraterone acetate for metastatic prostate cancer.

Sonpavde G.

Lancet Oncol. 2012 Oct;13(10):958-9. doi: 10.1016/S1470-2045(12)70392-3. No abstract available.

PMID:
22995649
10.

Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib.

Beltran H, Kaur G, de EspaƱa CG, Tagawa ST.

Asian J Androl. 2014 Jul-Aug;16(4):568-9. doi: 10.4103/1008-682X.127822. No abstract available.

11.

Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.

Bernardi D, Talamini R, Zanetti M, Simonelli C, Vaccher E, Spina M, Tirelli U.

Prostate Cancer Prostatic Dis. 2004;7(1):45-9.

PMID:
14999238
12.

Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.

Bryce A, Ryan CJ.

Clin Pharmacol Ther. 2012 Jan;91(1):101-8. doi: 10.1038/clpt.2011.275. Review.

PMID:
22130117
13.

Perspective on "Chemotherapy for advanced prostate cancer: 25 years later": is it a mirage or an oasis?

Haines IE, Stanley RM.

J Clin Oncol. 2008 Aug 20;26(24):4049-50; author reply 4051. doi: 10.1200/JCO.2008.18.3319. No abstract available.

PMID:
18711202
14.

Febrile neutropenia and infection in the ASCENT studies.

Fink M.

J Clin Oncol. 2011 Nov 10;29(32):4337; author reply 4337-8. doi: 10.1200/JCO.2011.37.9347. No abstract available.

PMID:
22010019
15.

New taxane treats advanced prostate cancer.

Thompson CA.

Am J Health Syst Pharm. 2010 Aug;67(15):1220. doi: 10.2146/news100052. No abstract available.

PMID:
20651307
16.

Prostate cancer: patient-reported outcomes of first-line abiraterone therapy.

Phillips R.

Nat Rev Urol. 2013 Nov;10(11):619. doi: 10.1038/nrurol.2013.236. No abstract available.

PMID:
24145475
17.

Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

Antonarakis ES.

Asian J Androl. 2011 Sep;13(5):663-4. doi: 10.1038/aja.2011.92. No abstract available.

18.

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.

Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L; Genitourinary Tract Group of the EORTC..

Oncology. 2005;68(1):2-9.

PMID:
15741753
19.

Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study.

Tralongo P, Bollina R, Aiello R, Di Mari A, Moruzzi G, Beretta G, Mauceri G, Conti G.

Tumori. 2003 Jan-Feb;89(1):26-30.

PMID:
12729357
20.

Editorial: States and state transitions are all that really matter.

Scher HI, Kelly WK.

J Urol. 2002 Dec;168(6):2451-3. No abstract available.

PMID:
12441937

Supplemental Content

Support Center